NeuroSense Therapeutics L... (NRSN)
NASDAQ: NRSN
· Real-Time Price · USD
1.20
0.03 (2.56%)
At close: Aug 15, 2025, 3:59 PM
1.20
0.42%
After-hours: Aug 15, 2025, 06:33 PM EDT
NeuroSense Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -9.9M | -11.42M | -12.21M | -12.65M | -12.65M | -12.74M | -13.17M | -13.28M | -13.55M | -11.82M | -9.38M | -6.74M | -5.59M | -5.06M | -5.3M | -4.67M |
Interest Income | 2.17M | 2.51M | 6.2M | 4.17M | 4.24M | 4.1M | 746K | 752K | 1.26M | 1.05M | 716K | 583K | 11K | 11K | 11K | n/a |
Pretax Income | -10.21M | -11.36M | -8.43M | -10.25M | -8.74M | -8.94M | -12.71M | -13.51M | -12.34M | -9.29M | -7.18M | -4.63M | -4.04M | -5.04M | -5.26M | -4.64M |
Net Income | -10.21M | -11.36M | -8.43M | -12.79M | -10.31M | -10.52M | -14.29M | -12.55M | -12.34M | -9.29M | -7.18M | -4.63M | -4.04M | -5.04M | -5.26M | -4.64M |
Selling & General & Admin | 4.2M | 4.85M | 5.17M | 5.28M | 5.71M | 6.22M | 6.56M | 6.71M | 7.14M | 6.9M | 5.65M | 4.38M | 2.5M | 1.04M | 822K | 427K |
Research & Development | 5.7M | 6.57M | 7.03M | 7.37M | 7.59M | 7.17M | 7.25M | 7.22M | 6.42M | 4.92M | 3.73M | 2.36M | 3.08M | 4.02M | 4.48M | 4.25M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 9.9M | 11.42M | 12.21M | 12.65M | 12.65M | 12.74M | 13.17M | 13.28M | 13.55M | 11.82M | 9.38M | 6.74M | 5.59M | 5.04M | 5.27M | 4.63M |
Interest Expense | 2.45M | 2.45M | 2.42M | 4.31M | 2.21M | 2.21M | 2.21M | 355K | 68K | 68K | 58K | 23K | 13K | 13K | 13K | 13K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 9.9M | 11.42M | 12.21M | 12.65M | 12.65M | 12.74M | 13.17M | 13.28M | 13.55M | 11.82M | 9.38M | 6.74M | 5.59M | 5.06M | 5.3M | 4.67M |
Income Tax Expense | -43.28K | -43.28K | -43.28K | -2.22M | -2.24M | -2.24M | -2.24M | -62K | n/a | n/a | -8.75K | -8.75K | -9.5K | -9.5K | -750 | -750 |
Shares Outstanding (Basic) | 21.65M | 19.81M | 18.05M | 15.4M | 15.38M | 13.62M | 13.62M | 11.79M | 11.78M | 11.59M | 11.6M | 11.31M | 10.94M | 10.77M | 10.94M | 5.58M |
Shares Outstanding (Diluted) | 21.65M | 19.81M | 18.05M | 15.4M | 15.38M | 13.62M | 13.62M | 11.79M | 11.78M | 11.59M | 11.6M | 11.31M | 10.94M | 10.77M | 10.94M | 5.58M |
EPS (Basic) | -0.6 | -0.7 | -0.53 | -0.86 | -0.76 | -0.82 | -1.11 | -1.03 | -1.02 | -0.78 | -0.63 | -0.42 | -0.37 | -0.56 | -0.67 | -0.65 |
EPS (Diluted) | -0.6 | -0.7 | -0.53 | -0.86 | -0.76 | -0.82 | -1.11 | -1.03 | -1.02 | -0.78 | -0.63 | -0.42 | -0.37 | -0.56 | -0.67 | -0.65 |
EBITDA | -9.9M | -13.28M | -10.38M | -12.87M | -12.87M | -10.87M | -14.65M | -12.57M | -12.27M | -10.77M | -8.66M | -6.16M | -5.58M | -5.05M | -4.15M | -3.2M |
EBIT | -9.9M | -13.28M | -8.19M | -10.68M | -10.68M | -8.68M | -14.65M | -12.57M | -12.27M | -10.77M | -8.67M | -6.17M | -5.59M | -5.06M | -5.29M | -4.67M |
Depreciation & Amortization | 21.5K | 21.25K | 19K | 37K | 34.75K | 32.5K | 30.25K | 27.25K | 25K | 22.75K | 22.75K | 3K | 3K | 3K | 1.12M | 1.45M |